Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | RHOA | P61586 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012602 | 0.87 | HSD17B1 (0.43) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4514314 | 0.84 | HSD17B1 (0.47) | HSD17B1HSD17B2RBP4MGLLPGR | |
| SCHEMBL5091095 | 0.84 | PGR (0.38) | CYP2C19RBP4PGRCHRM2CHRM1 | |
| SCHEMBL5103709 | 0.80 | GPR142 (0.40) | RBP4SCD5PGRRIPK1 | |
| SCHEMBL5090958 | 0.79 | PGR (0.38) | CYP2C19RBP4PGRCHRM2CHRM1 | |
| SCHEMBL5090969 | 0.79 | SLC9A1 (0.38) | CYP3A4CYP2C9CYP2C19RBP4CYP2D6 | |
| SCHEMBL13998575 | 0.79 | SLC9A1 (0.38) | CYP3A4CYP2C9CYP2C19RBP4CYP2D6 | |
| SCHEMBL5103257 | 0.77 | RBP4 (0.35) | RBP4SCD5PGRRIPK1CHRM2 | |
| SCHEMBL5091903 | 0.75 | MEN1 (0.37) | RBP4PGRCHRM2CHRM1CHRM3 | |
| SCHEMBL4519627 | 0.73 | GPR119 (0.47) | HSD17B1HSD17B2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| EP-1836196-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069275-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | HSD17B1 769/4885HSD17B2 920/4885CYP3A4 398/4885 |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | HSD17B1 769/4885HSD17B2 920/4885CYP3A4 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.